Skip to content
Screener

Royalty Pharma RPRX Equity Method Income

Equity Method Income at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$18.28M-17.5%
Innoviva, Inc. logo
Innoviva, Inc.INVA
-$131.83M-1,108%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.75M+60.8%

Other financials

Income statement

See full
Revenue$674.1M+16.5%
Operating income$133.1M-36.5%
Net income$17.9M-44.4%
EPS (diluted)$0.04-42.9%

Balance sheet

See full
Cash & equivalents$812.0M+28.5%
Total debt$9.0B+11.7%
Total equity$9.8B+3.1%
Total assets$19.8B+8.2%

Cash flow

See full
Operating cash flow$728.5M+100%

Valuation

See full
Market cap$25.6B+63.7%
Enterprise value$33.75B+46.5%
P/E31.4×+16.1×
P/S10.1×+3.3×

Profitability

See full
Operating margin59.6%-20.2pp
Net margin32.1%-12.3pp

Returns & leverage

See full
Return on equity8.5%-2.2pp
Debt / equity0.9×+0.1×
Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:02 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001802768-26-000015
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Total operating expense, net541,022368,866608,561402,932
Operating income133,119209,799696,156743,980
Other (income)/expense
Equity in earnings of equity method investees(4,077)(2,693)(25,835)(9,136)
Interest expense93,61768,668187,339133,929
(Gains)/losses on equity securities(69,156)30,553(48,990)76,431
Losses on available for sale debt securities34,88027,42041,56030,701
Interest income(5,127)(8,327)(11,356)(19,617)

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's equity method income?
Royalty Pharma (RPRX) reported equity method income of $4.08M in Q2 2026.
How has Royalty Pharma's equity method income changed year-over-year?
Royalty Pharma's equity method income increased by 51.4% year-over-year, from $2.69M to $4.08M.
What is the long-term trend for Royalty Pharma's equity method income?
Over 4 years (2021 to 2025), Royalty Pharma's equity method income has grown at a 10.5% compound annual growth rate (CAGR), from -$19.49M to $29.09M.
What does equity method income mean?
The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.

Ask your AI about Royalty Pharma's equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude